RENN Health Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.5/10
Best for: per-drug pages that each carry their own price, if you can accept an unnamed operator
RENN Health falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the plan
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
RENN Health sells compounded semaglutide from $149/mo and compounded tirzepatide from $199/mo on a subscription model, with three- and six-month bundles offered at a further discount. It names both molecules and gives each its own page with the price on it. Its Terms of Condition name no legal entity, no pharmacy and no medical group, and state only that governing law is the laws of the United States rather than a named state.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to RENN Health
Luvo Health
Best for: moving between compounded and brand without changing seller
Editorial score · methodology
Strut Health
Best for: semaglutide at $99/month, 48% under the register median
Editorial score · methodology
Pallas Health
Best for: knowing which pharmacy fills the vial — it names Belmar Pharmacy
Editorial score · methodology
RENN Health at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Pricing model
- Flat — dose increases don't raise the monthly price
- What's included
- Medication · Consult · Shipping
- FDA status
- No FDA warning letter on record
How RENN Health scores
Six columns, each one computed from something RENN Health has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
6.9/10$199/month is 23% below the register median of $259 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
5.5/10does not name a dispensing pharmacy; shows a price before asking for health information. Our verification confidence is low.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on RENN Health
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: low.
What signing up with RENN Health involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1RENN Health publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3RENN Health does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $149, tirzepatide $199. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether RENN Health serves your state cannot be confirmed from its site.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Cancelling RENN Health
Read from what RENN Health publishes in its own terms. Where a line says the seller does not publish something, that is the finding — we looked and it is not stated. Terms change; check the seller’s current policy before you subscribe.
- Minimum commitment
- Not stated
- Refund policy
- Not published by the seller
GLP-1 medications RENN Health offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
Semaglutide page: "start for as low as $149/mo". Homepage adds "Predictable monthly pricing starting at $149/month" and "3 and 6-month bundles with stack discounts".
Tirzepatide page carries $199 on the same as-low-as basis.
Check the price yourself before you pay
Every figure here was read off RENN Health's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $149 a month, within the normal band around this register's $189 median for the same drug and form
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly price is recorded as flat across doses, so it does not climb as the dose is titrated up
- The monthly figure covers medication, consult, shipping
- No FDA warning letter matched this operator when we searched our enforcement register
Against it
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What RENN Health charges
RENN Health does not publish a standing monthly price. That is a choice, and it means you cannot compare it against anything until you have gone through an intake and been quoted. When you get that quote, ask specifically for the ongoing monthly figure and what it includes — not the first-month rate, and not a program total divided by its length.
What RENN Health dispenses
RENN Health prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
What we could verify
RENN Health publishes little that can be checked from outside an intake. We searched the federal warning-letter record for this operator and came back with nothing. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to compare prices before committing time to an intake — there is no published figure to compare.
- You need to bill insurance. Like most of this market, this is cash-pay.
It fits if
- you want the price to stop moving as your dose climbs
Our read
We cannot tell you whether RENN Health is priced well, because it does not say. That is not automatically disqualifying — plenty of legitimate operators quote after intake — but it does mean the comparison has to happen after you have spent the time, which is the wrong order for the buyer. Collective is the nearest comparison we track, and worth reading alongside this.
The Bottom Line
RENN Health falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay RENN Health
Check today's price, then book the free consultation.
Where RENN Health is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Sources
Cited across this RENN Health review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of September 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See RENN Health's current pricing
The free consultation is where you learn whether you qualify, and what it costs today.